For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/
Daiichi Sankyo Selects Research Partners for TaNeDS Collaborative Drug Discovery Project
Tokyo, Japan (November 10, 2015)- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has selected research partners for its 2015 TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project.
TaNeDS, which began in 2011 as part of Daiichi Sankyo’s open innovation program, selects researchers from universities and public research centers in Japan, and Daiichi Sankyo will soon begin signing agreements with this year’s selected parties to initiate collaborative research.
1. Total entries: 227
2. Selected parties: 20
3. Selections by entry type
|
Project type
|
Entries
|
Passed second selections
|
Final selections
|
- Daiichi Sankyo's Desired Research Themes*1
|
217
|
34
|
19
|
|
a. Drug discovery target verification
|
112
|
9
|
8
|
|
b. Drug discovery target investigation
|
98
|
10
|
3
|
|
c. Drug discovery technology development/verification
|
60
|
12
|
6
|
|
d. Pharmaceutical technology
|
12
|
3
|
2
|
- B. Daiichi Sankyo RD Novare's Desired Research Themes*2
|
10
|
1
|
1
|
*1 Type A contains 4 categories, thus entries with multiple categories are counted once for each category.
*2 Daiichi Sankyo RD Novare Co., Ltd. (hereafter, RD Novare), Daiichi Sankyo’s wholly owned subsidiary, joined TaNeDS to promote the development of novel technology platforms for drug discovery from 2013.
4. Selections by research theme
|
Desired research themes
|
Entries
|
Passed second selections
|
Final
selections
|
|
A. Daiichi Sankyo's Desired Research Themes
・Oncology
|
128
|
8
|
4
|
|
・Other disorders
|
93
|
11
|
8
|
|
・Biologics
|
5
|
0
|
0
|
|
・DDS
|
21
|
4
|
1
|
|
・Pathological model/unique cell-based assays/vital imaging
|
8
|
1
|
0
|
|
・in silico models related to drug effect estimates/pathological clarification
|
10
|
0
|
0
|
|
・ADME (Drug Absorption, Distribution, Metabolism, Excretion)
|
10
|
2
|
2
|
|
・Drug safety
|
8
|
3
|
2
|
|
・Measuring technology related to biomarker
|
12
|
1
|
0
|
|
・Vaccines
|
6
|
1
|
0
|
|
・New synthetic technology
|
6
|
2
|
2
|
|
・Biomedicine safety technology
|
3
|
0
|
0
|
|
・Chemical compounds/drug analysis technology
|
3
|
1
|
0
|
|
B. RD Novare's Desired Research Themes
・Drug discovery and development technology platform research
|
10
|
1
|
1
|
|
Total
(Entries with multiple themes are counted once for each theme)
|
323
|
35
|
20
|
*For more information about the TaNeDS program, please visit the Daiichi Sankyo corporate website (in Japanese): https://www.daiichisankyo.co.jp/corporate/rd/taneds/